A user on TRT reported plans to combine Tesamorelin with Ipamorelin after being on growth hormone for over two years. They expressed some concern regarding potential down-regulation and the loss of the peptide’s ability to maintain high therapeutic IGF-1 levels (target 300-350 ng/ml) over time.